The most clinically advanced proteolysis-targeting chimera, bavdegalutamide, seems to work best against two molecularly defined subtypes of advanced prostate cancer. According to phase I/II trial data presented at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium, the androgen receptor degrader most commonly shows antitumor activity among patients with T878X or H875Y mutations.

©2022 American Association for Cancer Research
2022
American Association for Cancer Research
You do not currently have access to this content.